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High throughput resistance 
profiling of Plasmodium falciparum 
infections based on custom 
dual indexing and Illumina next 
generation sequencing-technology
Sidsel Nag1,2, Marlene D. Dalgaard3, Poul-Erik Kofoed4,5, Johan Ursing5,6, Marina Crespo1,2, 
Lee O’Brien Andersen7, Frank Møller Aarestrup8, Ole Lund3 & Michael Alifrangis1,2
Genetic polymorphisms in P. falciparum can be used to indicate the parasite’s susceptibility to 
antimalarial drugs as well as its geographical origin. Both of these factors are key to monitoring 
development and spread of antimalarial drug resistance. In this study, we combine multiplex PCR, 
custom designed dual indexing and Miseq sequencing for high throughput SNP-profiling of 457 malaria 
infections from Guinea-Bissau, at the cost of 10 USD per sample. By amplifying and sequencing 15 
genetic fragments, we cover 20 resistance-conferring SNPs occurring in pfcrt, pfmdr1, pfdhfr, pfdhps, 
as well as the entire length of pfK13, and the mitochondrial barcode for parasite origin. SNPs of interest 
were sequenced with an average depth of 2,043 reads, and bases were called for the various SNP-
positions with a p-value below 0.05, for 89.8–100% of samples. The SNP data indicates that artemisinin 
resistance-conferring SNPs in pfK13 are absent from the studied area of Guinea-Bissau, while the 
pfmdr1 86 N allele is found at a high prevalence. The mitochondrial barcodes are unanimous and 
accommodate a West African origin of the parasites. With this method, very reliable high throughput 
surveillance of antimalarial drug resistance becomes more affordable than ever before.
During the past fifteen years the global malaria case numbers are estimated to have decreased by 18% and overall 
death rates by 48%1. According to the WHO, fast-acting and efficacious antimalarial treatment is a key contribu-
tor to this development1. A major challenge in the further battle against malaria is therefore the persistent devel-
opment and geographical spread of antimalarial drug resistance2. Unfortunately, tolerance and/or resistance has 
emerged towards all of the existing antimalarial treatments, and some areas struggle with highly multi-resistant 
parasites that represent a major threat to the rest of the malaria-endemic world3.
The current first-line treatments for P. falciparum malaria are the artemisinin-based combination therapies 
(ACTs). These are based on artemisinin derivatives4 combined with a partner drug: either amodiaquine (AQ), 
mefloquine (MQ), lumefantrine (LMF), piperaquine (PPQ) or sulphadoxine-pyrimethamine (SP)1. Due to the 
previous use of all of the partner drugs, except for LMF, as monotherapies in treating malaria, the parasites 
may already have developed tolerance/resistance towards these drugs. Furthermore, despite committed imple-
mentation of ACTs in all sub-Saharan African (SSA) countries, household surveys have estimated that quinine 
(QN) as well as abandoned drugs for treatment of malaria, namely chloroquine (CQ) and SP still account for 
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approximately half of the antimalarial treatments given to children in SSA in 20141. Lastly, two strategies of 
SP-based preventive treatment; intermittent preventive treatment of pregnant women (IPTp) and seasonal 
malaria chemoprevention (SMC, combining SP with AQ) are implemented in a number of countries1. P. falci-
parum parasites are therefore still under selective pressure from a wide range of antimalarial drugs.
Among the P. falciparum genes hitherto implicated in conferring antimalarial resistance, the literature has 
focused on single nucleotide polymorphisms (SNPs) occurring in mainly five P. falciparum genes; P. falciparum 
chloroquine resistance transporter (pfcrt), P. falciparum multidrug resistance gene 1 (pfmdr1), P. falciparum dihy-
drofolate reductase (pfdhfr), P. falciparum dihydropteroate synthase (pfdhps), and most recently P. falciparum 
putative kelch protein (pfK13)5–20. While specific and highly conservative SNPs have been identified globally in 
pfcrt, pfmdr1, pfdhfr and pfdhps, studies indicate that tolerance/resistance towards artemisinins may rather be 
conferred by a variety of mutations in the propeller region of pfK1315, 21. So far 13 singly occurring mutations in 
the propeller region of pfK13 have been identified in SE Asia and confirmed to mediate slow clearance time of 
the parasites. However, numerous low frequency pfK13 polymorphisms, especially synonymous ones, have been 
identified in Africa, and are hitherto not linked to artemisinin resistance. Temporal surveillance of the prevalence 
of these SNPs provides crucial knowledge on development and geographic spread of antimalarial drug resistance 
in P. falciparum populations, which are important for antimalarial drug policy decisions for instance as shown 
regarding IPTp22.
The geographic origin of the parasites is of major importance to a surveillance scheme aiming to monitor 
global emergence and spread of resistance, and perhaps thereby attempt to hinder or delay the spread of artemis-
inin resistance from South East Asia to SSA23–25. According to a recently published study, recent geographic origin 
of the parasites can be estimated with a genetic barcode consisting of well-defined SNPs located in the mitochon-
drial and apicomplexan genomes26. A surveillance scheme aiming to analyse all SNPs in question is therefore a 
long process and requires sequencing.
The knowledge thus exists for temporal and geographical surveillance of antimalarial drug resistance includ-
ing geographic flow of parasites between continents. For such a surveillance scheme to be operational, it requires 
high throughput SNP-profiling through sequencing, while allowing for identification and grouping of the data 
pertaining to an individual infection. A number of methods have been developed for SNP-detection, includ-
ing PCR-RFLP, PCR-SSOP-ELISA, real-time PCR, LAMP and custom DNA micro-arrays27–39, however, only 
few of them are suitable for large-scale screening. Methods that allow for actual fragment sequencing are lim-
ited to Sanger sequencing and next-generation sequencing (NGS), where NGS in particular is highly suited for 
high throughput methodologies. So far, two NGS-based methods of relevance for surveillance of antimalarial 
drug resistance have been published40, 41, whereof only one allows for barcoding and thereby track-keeping of 
sequences pertaining to a specific infection41.
In this study, we present proof-of-concept of using custom dual indexing on the Illumina NGS (Miseq) plat-
form, for targeted high throughput sequencing of genetic loci related to antimalarial drug resistance and mito-
chondrial barcoding of the infecting P. falciparum parasites. Application of an NGS platform vastly increases the 
amount of raw data acquirable as compared to previously applied methods, and thereby provides the opportunity 
for implementation of a high throughput methodology. The Illumina platform described in the present study is 
designed for dual indexing of samples, which consists of a 3′ and 5′ individual barcode, which allow the user to 
connect every sequence generated to a sample (infection) of origin. In our method, we have applied custom dual 
indexing based on primers that were custom-designed, which allows for a substantial increase in barcode combi-
nations and therefore in the number of samples that can be run simultaneously.
Results
A total of 457 patients of all ages attending the Bandim and Belem Health Care Centres in Guinea-Bissau, were 
diagnosed with malaria with an RDT, and donated their used RDTs to the current study. Additionally, out of these 
patients, 318 patients gave consent to donate venous blood, which was processed and dried on filter paper (see 
methods). See Fig. 1 for sampling overview and demographic details. The 318 patients who donated filter paper 
samples were also diagnosed by microscopy. Parasite densities ranged from 15 parasites/200 leucocytes to 500 
parasites/13 leucocytes. Filter paper samples were used for full resistance profiling and mitochondrial barcoding 
while RDTs were only used for mitochondrial barcoding.
Sample calling and sensitivity. Several steps in the protocol of the platform presented in this study have 
been optimised for analysis of large numbers of samples. Multiplexing of the gene-specific PCRs followed by 
further multiplexing of the index PCRs and finally pooling of samples prior to sequencing (see Figs 2 and S1 for 
details), are all elements that meet the necessity of efficiency in high throughput surveillance, but which reduce 
the possibility of keeping track of all the individual PCR fragments and samples in the analysis. It is therefore 
crucial to investigate to what extent individual amplicons and samples were lost during the process. All of the 463 
custom dual index combinations (457 samples and 6 controls) were successfully called from the sequencing data 
with belonging amplicon sequences, and hence no samples had been completely lost, however some had too few 
reads for SNP-analysis. Out of the 318 samples that were resistance-profiled, 264 were successfully sequenced in 
all resistance-conferring positions. Of the 54 samples that were not completely profiled, 45 were lacking adequate 
sequencing of a single amplicon, 7 were lacking adequate sequencing of 2 amplicons, while 2 samples were lacking 
adequate sequencing of 3 amplicons. Mitochondrial barcodes were successfully generated for all 457 samples. 
There was no correlation between parasite density and successful resistance-profiling/amplicon coverage.
Amplicon representation and coverage. The various amplicons sequenced in this study are depicted 
in Fig. 3. Amplicon representation was defined as the presence of sequences corresponding to a specific ampli-
con within the individual sample. Base calling was defined as the determination of a base at a specific position 
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within the amplicon, and was also assessed for individual samples. Both amplicon representation and successful 
base calling for the individual samples was assessed after performing quality trimming of the raw sequences (see 
methods). The amplicon representation (listed in Table 1) was estimated as a presence/non-presence of sequences 
belonging to a specific amplicon in the individual samples (read count >0) and ranged from 98.1% to 100%. 
Successful base calling (determined as bases called with a minimum z-score of 1.96 and p-value ≤ 0.05) was 
estimated for all surveyed SNP-positions, as well as positions from each mitochondrial amplicon, and ranged 
from 89.8% to 100%. Average read count for the different resistance-conferring SNPs (per sample) varied from 
250 reads to 4,734 reads (mean = 1,520 reads for individual bases, and 1,725 reads for entire amplicons, Table 1). 
Average read count over all amplicons was 2,043.
SNP-data from P. falciparum positive subjects attending the Bandim and Belem Health Care 
Centres in Guinea-Bissau. Table 2 lists the results of frequencies of known molecular markers in pfcrt, 
pfmdr1, pfdhfr and pfdhps. Samples with <75% unanimous reads were categorized as mixed, and therefore 
counted in both the reference and alternative group. Furthermore, Table 3 lists other polymorphisms found (only 
pfcrt and pfmdr were found to have additional polymorphisms) and Table 4 describes all polymorphisms found in 
pfK13. The data acquired for the six control strains is listed in Table 5. Finally, Fig. 4 illustrates the distribution of 
the various haplotypes of pfcrt, pfmdr, pfdhfr and pfdhps (excluding mixed infections).
Polymorphisms found in pfcrt. A fragment covering c42–131 of the pfcrt gene, was sequenced (Fig. 3). The c76 
K/T alleles were present in almost equal amounts (including mixed K/T infections: 56.5% and 52.4%, respectively, 
Table 2), as was the case for the c72–76 haplotypes CVMNK/CVIET (47.8% and 43.5% respectively, mixed infec-
tions omitted, Fig. 4). Additionally, the CVIEK (n = 12) and the CVMNT (n = 12) were identified in few samples. 
Furthermore, a non-synonymous polymorphism at c128 (L to I) was found in four samples (1.3%), twice in mixed 
infections (Table 3).
Polymorphisms found in pfmdr1. In total, 1369 bases were sequenced in pfmdr1, covering c11–162, c938–1080, 
and c1134–1297 (Fig. 3). The pfmdr1 c86N was found in 92.8% of the samples, while pfmdr1 c86Y was found in 
only 9.7% of samples (Table 2). pfmdr1 c184 was not analysed due to a design flaw. No samples were found to have 
mutations at pfmdr1 c1034 and c1042, while only 2 samples had the pfmdr1 c1246Y allele (Table 2). Additionally, 
non-synonymous mutations were found at c12 N→T (2 samples), c968 G→V (1 sample), and c1199 N→K (16 
samples plus 9 mixed) (Table 3). Synonymous mutations were found at c102 (12 samples plus 6 mixed), c149 (7 
Figure 1. Patient recruitment and demography. Patients of all ages attending the Bandim or Belem health care 
centres, with a fever or a history of fever within the past 24 hours, were tested for malaria positivity with an RDT. 
If the patient tested positive, the patient was asked for informed consent in donating the RDT used to test them 
for malaria infection. The malaria-positive patients were furthermore asked for informed consent in donating 
venous blood. If consent was given for this procedure, the blood was drawn and the patient was included in the 
study. In total, 457 malaria-positive patients gave consent to donate their RDTs and 318 of these patients gave 
consent to donate venous blood. If venous blood was donated, the RDT was not used for the analysis.
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samples), c1062 (1 sample), c1069 (16 samples plus 6 mixed), c1137 (4 samples plus 1 mixed) and c1139 (1 sample 
plus 1 mixed) (Table 3). A total of 262 samples were completely profiled in pfcrt and pfmdr1, and amongst these 
samples we found that 41.2% carried both the pfcrt c72–76 CVIET haplotype and the pfmdr1 c86N allele.
Polymorphisms found in pfdhfr. A fragment of 461 bp was sequenced from pfdhfr, reaching from c11–164 
(Fig. 3). The c16 A→V and the c164 I→L mutations were completely absent while the c51 N→I mutation was 
found in 88% of samples, the c59 C→R mutation was found in 87.1% of samples and the c108 S→N mutation was 
Figure 2. Primer and fragment design for library preparation. The P. falciparum gene fragments of interest 
are amplified with gene-specific primers, in a “gene-specific PCR” (1). The primers anneal to loci in the P. 
falciparum genome, while encoding non-annealing overhangs, which are then incorporated into the PCR 
products during amplification. The non-annealing overhangs are identical on all gene-specific primers, and 
serve as annealing site for the index primers (2), which can in turn anneal to all amplified gene fragments. The 
index primers also encode individual 8-base indices as well as an adaptor sequence. The index and adapter 
sequence are incorporated into the PCR product (denoted amplicon from here on), which can then bind to 
the Miseq flow cell through the adaptor sequence, and be identified through sequencing of it’s unique index 
combination.
www.nature.com/scientificreports/
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found in 92.4% of samples (Table 2). The prevalence of the pfdhfr triple mutant haplotype (51I, 59 R, 108 N) was 
82.4% (mixed infections omitted, Fig. 4).
Polymorphisms found in pfdhps. Two fragments covering 887 bp reaching from c358–645 were sequenced for 
pfdhps (Fig. 3). The c431 V→I mutation was found in one sample, the c436 A→S polymorphism was found in 
35.7% of samples, and the c437 A→G was found in 66.8% of samples. In contrary, the c540K→E mutation was 
only observed once in a mixed infection, the c581 A→G mutation was not observed at all and the c613 A→S was 
found once (Table 2). A total of 233 samples were completely profiled in pfdhfr and pfdhps, and amongst these 
samples we found that 52.8% carried the combined pfdhfr/pfdhps quadruple mutant (consisting of pfdhfr c51I, 
c59R, c108N + pfdhps c437G).
Polymorphisms found in pfK13. The entire length of pfK13 (excluding forward primer site of amplicon K13.1 
and reverse primer site of amplicon K13.5, see Fig. 3) was analysed for polymorphisms, and listed in Table 4. The 
c189T allele was found in 57.9% of the samples, while mixed c189L/T were found in 11.6% of samples. The c189N 
allele, was found in 3.5%, while both c189L/N were found in 1.6%. Other non-synonymous polymorphisms, of 
which 2/8 were located within the propeller region of pfK13 (marked as blue in Table 3), were found at c22 R→K 
(1 sample), c84 L→K (1 sample), c112 G→E (1 sample plus 2 mixed), c114 L→Q (3 samples, 1 mixed), c149 
T→S (2 samples), c274 H→Y (1 sample), c578 A→S (3 samples plus 2 mixed) and c698 F→I (1 sample). Also, a 
number of synonymous polymorphisms were found in pfK13, 4/7 of which were located in the propeller region: 
c19 (1 sample), c107 (1 sample), c139 (2 samples plus 1 mixed), c469 (3 samples plus 3 mixed), c478 (3 samples), 
c627 (1 sample) and c690 (1 sample).
Mitochondrial barcode. Mitochondrial barcodes were successfully provided for all 457 samples. The results 
revealed a unanimous pattern across all samples, namely the CTTAG barcode (corresponding to nucleotide posi-
tions 772-853-973-1283-2382), which corresponds to the barcodes published for West-Africa26.
Discussion
Multi-drug resistant P. falciparum threatens the current trend of decreasing malaria burden observed in many 
malaria endemic countries. Molecular surveillance of antimalarial resistance is becoming an attractive oper-
ational tool to determine temporal and geographical emergence and spread of drug resistance. However, effi-
cient molecular surveillance requires high throughput, sequence-based SNP analysis in order to assess all the 
SNPs and genes playing a role in antimalarial drug resistance. This study applied Illumina’s Miseq NGS tech-
nology of paired-end sequencing on samples collected from patients with P. falciparum infections to provide a 
Figure 3. Amplicon design. In the current study, we have analysed one fragment including five SNPs in pfdhfr, 
three fragments including four SNPs in pfmdr1, one fragment including five SNPs in pfcrt, two fragments 
including six SNPs in pfdhps, all of pfK13, and three fragments including five SNPs in the mitochondrial genome 
of P. falciparum. The figure illustrates the length and placement of the fragments in the different genes, as well as 
the nucleotide/codon positions of the SNPs of interest.
www.nature.com/scientificreports/
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high-throughput molecular surveillance method, which is cost-effective as compared to other published meth-
odologies including classic Sanger sequencing.
The sequenced amplicons cover the most established molecular markers of drug resistance in pfcrt, pfmdr1, 
pfdhfr and pfdhps, as well as the entire pfK13 gene. Additionally, the sequenced amplicons also covered the SNPs 
constituting the mitochondrial barcode linked to the geographical origin of P. falciparum. The method is PCR 
based and applies several PCR steps, ruling out the possibility of assessing gene copy numbers, as would be 
relevant for pfmdr1 and the recently identified plasmepsin42. However, the number and identity of amplicons 
incorporated in the analysis is only dependent on primer design. The method is therefore highly adaptable, since 
polymorphisms for analysis can easily be incorporated, including for example the exonuclease E415G polymor-
phism, which has recently been identified as a marker for PPQ resistance42, pfmdr1 c184, as well as SNPs occur-
ring in the apicoplast, which can be used in further specifying the origin of the infecting parasite42. Importantly, 
the method is sequencing-based, which generates the possibility of monitoring entire genes, which is necessary 
in the case of polymorphisms in pfK13 and their relation to artemisinin resistance. It also opens the possibility of 
identifying other polymorphisms that are not normally analysed with SNP-detection based methods, as is seen 
for pfcrt and pfmdr1 in this study. The unique 5′- and 3′- indices enable identification of individual samples, and 
it is therefore feasible to analyse various genes belonging to the same infection, which again is necessary when 
monitoring parasite susceptibility to combination therapies, such as SP and ACTs.
The possibility of customising the library preparation is the reason the Illumina platform was chosen over 
other platforms that would provide longer sequences and hence require fewer amplicons for sequencing of entire 
genes. At 10 USD per sample, the current study is approximately 7x cheaper than an alternative protocol pub-
lished for Ion Torrent41. We have created 50 unique indices (Table S2), which make it possible to create 2450 
unique dual index combinations (50 × 50–50) and hence run as many samples on the Miseq simultaneously. It 
is thereby feasible to reduce sample costs to less than 4 USD per sample, approximating only 5 USD per sample 
PCR product CODON
Amplicon representation Successful base-calling average 
read countcount percentage count percentage
Pfcrt.2 72 324 100 320 98,8 1129
Pfcrt.2 73 324 100 320 98,8 1129
Pfcrt.2 74 324 100 320 98,8 1128
Pfcrt.2 75 324 100 320 98,8 1128
Pfcrt.2 76 322 99,4 320 98,8 1128
Pfdhfr.1 16 324 100 323 99,7 2463
Pfdhfr.1 51 324 100 323 99,7 2335
Pfdhfr.1 59 324 100 323 99,7 2324
Pfdhfr.1 108 324 100 322 99,4 2448
Pfdhfr.1 164 324 100 323 99,7 2385
Pfdhps.3 431 324 100 322 99,4 774
Pfdhps.3 436 324 100 322 99,4 767
Pfdhps.3 437 324 100 322 99,4 767
Pfdhps.4 540 313 96,6 291 89,8 250
Pfdhps.4 581 320 98,8 311 96,0 1575
Pfdhps.4 613 320 98,8 311 96,0 1601
Pfmdr1.1 86 324 100 324 100 4734
Pfmdr.7 1034 318 98,1 307 94,8 440
Pfmdr.7 1042 318 98,1 307 94,8 440
Pfmdr.8 1246 324 100 322 99,4 1467
PfK13.1 84 324 100 324 100 2008
PfK13.2 224 322 99,4 320 98,8 755
PfK13.3 329 324 100 324 100 1511
PfK13.4 469 323 99,7 323 99,7 5963
PfK13.5 635 324 100 324 100 5816
Mito.1 base 772 324 100 324 100 2496
Mito.2 base 1283 324 100 324 100 3224
Mito.3 base 2383 324 100 324 100 5015
Table 1. Amplicon Amplicon representation, successful base calling and average read count. The table shows 
how many of the samples were found with pertaining reads corresponding to the various amplicons, after 
quality trimming (as sample count and percentage), as well as for how many samples successful base-calling 
was performed (requires a minimum z-score of 1.96). For pfK13 and for the mitochondrion, a position for each 
amplicon was analysed. Some of the SNP positions are located in the same amplicon. The table also lists the 
name of the individual amplicons, and Fig. 3 can be referred to for illustrations of the length and position of the 
amplicons within the various genes.
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already with only 800 samples. When running large numbers of samples simultaneously, the challenge consists 
of controlling the process of mixing all amplicons in equal amounts prior to sequencing (see Figure S1 for pro-
tocol overview and Figures S2 and S3 for example data). Targeting the desired depth of coverage of the various 
amplicons can be approximated through this process, also if certain amplicons are to be sequenced deeper than 
others. However, varying depth of coverage should be expected, especially if multiplex PCR is applied for gene 
amplification and subsequently during the library preparation, as is the case in our study. Sequencing bias may 
also occur when using the library design applied43, leading to vastly differentiated depth of coverage of the dif-
ferent amplicons. This is due to a potential mismatch between the Illumina Nextera sequencing primer and the 
designed amplicons, which can also occur when applying the Illumina Nextera Library Preparation Kit43. It is 
noteworthy, however, that despite such a bias, the final coverage can still be expected to be adequate, due to the 
mere sequencing capacity of the Illumina Miseq (amounting to 7.5 billion bp per run).
Reference codon Alternative codon Reference freq. Alternative freq. Mixed freq. Total count
pfcrt_72 C S 100.0% 0.0% 0.0% 314
pfcrt_73 V — 100.0% 0.0% 0.0% 314
pfcrt_74 M I 57.0% 52.9% 9.9% 314
pfcrt_75 N E 57.0% 52.9% 9.9% 314
pfcrt_76 K T 56.5% 52.4% 9.8% 317
pfdhfr_16 A V 100.0% 0.0% 0.0% 317
pfdhfr_51 N I 18.6% 88% 6.6% 317
pfdhfr_59 C R 18.9% 87.1% 6.3% 317
pfdhfr_108 S N 12.6% 92.4% 4.7% 316
pfdhfr_164 I L 100.0% 0.0% 0.0% 317
pfdhps_431 V I 99.4% 0.6% 0.0% 316
pfdhps_436 A S 74.3% 35.7% 10.1% 316
pfdhps_437 A G 50.3% 66.8% 17.1% 316
pfdhps_540 K E 100.0% 0.3% 0.3% 286
pfdhps_581 A G 100.0% 0.0% 0.0% 306
pfdhps_613 A S/T 99.3% 0.7% 0.0% 306
pfmdr1_86 N Y 92.8% 9.7% 2.5% 318
pfmdr1_1034 S C 100.0% 0.0% 0.0% 301
pfmdr1_1042 N D 99.7% 0.3% 0.0% 301
pfmdr1_1246 D Y 99.0% 1.0% 0.0% 313
Table 2. Prevalence of resistance-conferring mutations. The table describes what frequencies of the samples 
that were found to harbor the reference SNPs versus the alternative SNPs (translated into codons) and how 
many of the samples were categorized as mixed infections. Note that mixed infections (noted as Mixed freq.) 
were counted in both the reference and alternative frequencies. The analysis was done for every SNP-position of 
interest in pfcrt, pfmdr1, pfdhfr and pfdhps.
Base 
position
Codon 
position
Reference 
base
Alternative 
base
Reference 
codon
Alternative 
codon
Reference 
freq.
Alternative 
freq.
Mixed 
freq.
Non-synonymous polymorphisms
pfcrt 382 128 T A L I 99.4% 1.3% 0.6%
pfmdr1
35 12 A C N T 99.4% 0.6% 0.0%
2903 968 G T G V 99.7% 0.3% 0.0%
3597 1199 T G N K 95.0% 7.8% 2.8%
Synonymous polymorphisms
pfmdr1
306 102 T C G G 96.3% 5.6% 1.9%
447 149 T G S S 97.8% 2.2% 0.0%
3186 1062 C T D D 99.7% 0.3% 0.0%
3207 1069 T G T T 94.8% 7.2% 2.0%
3411 1137 A C Y Y 98.8% 1.6% 0.3%
3417 1139 A G P P 99.7% 0.6% 0.3%
Table 3. Other polymorphisms in pfcrt and pfmdr1. The table describes polymorphisms identified amongst 
the 318 resistance-profiled samples in pfcrt and pfmdr1 other than the positions of interest indicated on Fig. 3 
and Table 2. The frequencies of both the reference and alternative are listed, as well as the frequency of mixed 
infections. Note that mixed infections were counted in both the reference and alternative frequencies.
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Base 
position
Codon 
position
Reference 
base
Alternative 
base
Reference 
codon
Alternative 
codon
Reference 
freq.
Alternative 
freq.
Mixed 
freq.
Non-synonymous K13 polymorphisms
65 22 G A R K 99.7% 0.3% 0.0%
252 84 A G L K 99.7% 0.3%
335 112 G A G E 99.7% 0.9% 0.6%
340 114 A C L Q 99.1% 1.3% 0.3%
445 149 A T T S 99.4% 0.6%
566 189 A C L T 53.8% 57.9% 11.6%
567 189 A T L N 98.1% 3.5% 1.6%
820 274 C T H Y 99.7% 0.3%
1732 578 G T A S 99.1% 1.6% 0.6%
2092 698 T A F I 99.7% 0.3%
Synonymous K13 polymorphisms
57 19 G A T T 99.7% 0.3%
321 107 T C S S 99.7% 0.3%
417 139 T C N N 99.4% 0.9% 0.3%
1407 469 C T C C 99.1% 1.9% 0.9%
1434 478 C G T T 99.7% 0.3%
1881 627 T A A A 99.7% 0.3%
2070 690 C A G G 99.7% 0.3%
Table 4. Polymorphisms in pfK13. The table describes the various polymorphisms found in pfK13 for the 
318 resistance-profiled samples, and the frequencies in which the reference and alternative base were found, 
as well as the frequencies of mixed infections. SNP positions written in italic indicate that they are located in 
the propeller region of pfK13. Note that mixed infections were counted in both the reference and alternative 
frequencies.
SNP
Control strains with listed codon/base (and read count)
3D7 7G8 DD2 K1 MRA_1238 MRA_1239
pfcrt_72 C (1238) S (1752) C (153) C (2013) C (1968) C (1753)
pfcrt_73 V (1238) V (1752) V (153) V (2013) V (1968) V (1753)
pfcrt_74 M (1238) M (1752) I (153) I (2013) I (1968) I (1753)
pfcrt_75 N (1238) N (1752) E (153) E (2013) E (1968) E (1753)
pfcrt_76 K (1238) T (1752) T (153) T (2013) T (1968) T (1753)
pfdhfr_16 A (3744) A (1954) A (148) A (1373) A (2646) A (1182)
pfdhfr_51 N (3561) I (1837) I (149) N (1302) I (2520) I (1129)
pfdhfr_59 C (3532) C (1823) R (137) R (1295) R (2513) R (1124)
pfdhfr_108 S (3721) N (1935) N (154) N (1355) N (2615) N (1167)
pfdhfr_164 I (3607) I (1901) I (155) I (1318) I (2534) L (1150)
pfdhps_431 I (568) I (1126) I (90) I (5233) I (1545) I (7437)
pfdhps_436 S (565) S (1119) F (101) S (5178) A (1537) S (7368)
pfdhps_437 G (565) G (1120) G (101) G (5174) G (1542) G (7370)
pfdhps_540 K (75) K (411) K (88) K (1196) E (294) Y (733)
pfdhps_581 A (403) A (1045) A (136) G (3614) A (828) A (1878)
pfdhps_613 A (403) A (1061) S (135) A (3730) A (858) A (1915)
pfmdr1_86 N (4543) N (1350) Y (540) Y (4758) N (6463) N (6628)
pfmdr1_1034 S (555) C (1417) S (98) S (1727) S (988) S (4078)
pfmdr1_1042 N (555) D (1417) N (98) N (1727) N (988) N (4078)
pfmdr1_1246 D (3111) Y (3189) D (236) D (1399) D (3262) D (6719)
pfK13_493 Y (3459) Y (2389) Y (172) Y (1987) H (3632) Y (5430)
pfK13_543 I (4001) I (3760) I (267) I (3801) I (4099) T (5698)
Mito_772 C (2977) C (3666) T (678) T (452) T (2496) T (2590)
Table 5. Control data. The table lists the acquired data for the control parasites. The data is listed as the acquired 
codon/base (only base for Mito_772, as the mitochondrial barcode is DNA-code based) followed by the amount 
of matching reads in parenthesis. None of the control samples were mixed genotypes.
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While gene haplotype analysis excludes analysis of mixed infections, frequencies of individual SNPs can be 
given for major and minor alleles as long as a minor allele is detectable. Since the aim of the current study was not 
only to provide frequency data, but also haplotype data, the cut off for mixed infections was set as <75% of the 
bases supporting a given base for a given position. This cut off, however, can be reduced and should be considered 
subjective to study purpose. The experimental limitations for the cut off are largely dependent on the achieved 
depth of coverage as well as the applied statistical probability applied for base calling.
The method applied in this study generated sequence data from pfcrt, pfmdr1, pfdhfr, pfdhps and pfK13 
from 318 P. falciparum samples. The polymorphisms discovered in pfK13 in the current study indicate no 
pfK13-mediated artemisinin tolerance in Bandim, Guinea-Bissau. Accordingly, an efficacy study published in 
2016 showed high efficacy of AL in the same area3. The majority of the non-synonymous polymorphisms found 
in pfK13 were located in the N-terminal region (not the propeller), in particular the pfK13 c189T was found at 
57.9%. The high prevalence of this SNP is consistent with previous studies in Africa and it has not been associ-
ated with artemisinin resistance15, 44, 45. Only two non-synonymous polymorphisms were found in the propeller 
region of pfK13: c578S and c698I. The pfK13 c578S has previously been identified at noteworthy frequencies in a 
number of SSA countries without clinical relevance3, 15, 25, 46. However, the data generated in this study cannot rule 
out any pfK13-independent mechanisms conferring resistance towards artemisinin, as well as the study cannot 
conclude on the treatment efficacy for the patients involved. Interestingly, a Kenyan study has recently published 
the presence of residual P. falciparum parasitemia at day 3 after treatment with either artemether-lumefantrine or 
dihydroartemisinin-piperaquine in 31.8% of the infected children47. A follow-up study furthermore rules out the 
responsibility of PfK13-encoded polymorphisms in in these day 3 positive cases48. Importantly, the mitochondrial 
barcodes indicated no recent import of P. falciparum parasites from South-East Asia, where artemisinin resistance 
is a reality. Mainly the first position in the barcode, base 772, would reveal recent South-East Asian origin, if it 
were a T instead of a C26. All four of the South-East Asian control parasites were found to have a T on position 
772 (DD2, K1, MRA-1238, MRA-1239, see Table 5). The pfcrt c76T polymorphism and the pfcrt c72–76 CVIET 
haplotype, were found in 52.4% and 43.5%, respectively. Almost all of the samples (90%) were pfmdr1 c86N. The 
pfdhfr triple mutant was present at 82.4%. The pfdhps c437G polymorphism was 66.8%, while the polymorphisms 
at codons 540, 581 and 613 known to occur further downstream in pfdhps in an East African context were either 
Figure 4. Haplotype distributions. Four genes were analysed for the distribution of different haplotypes, due 
to the relevance of certain haplotypes in conferring different levels of tolerance/resistance towards various 
antimalarial drugs. The figure illustrates the distribution of haplotypes (mixed infections omitted) found in 
pfcrt, pfmdr1, pfdhfr and pfdhps. Complete haplotypes could be assigned to 278 samples for pfcrt, 291 samples 
for pfmdr1, 284 samples for pfdhfr and 225 samples for pfdhps.
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absent or only found in single samples. The pfdhps c431V, which recently has been found in Nigeria and has been 
proposed as a molecular reason for the lack of mutations downstream of c437 in pfdhps in West-African P. falci-
parum parasites49, 50 was only found in one sample. These findings are consistent with previously published find-
ings from the same area51, while also indicating an increase in the frequency of pfmdr1 c86N51, consistent with 
the recommendation and use of both AL and QN in treatment of malaria in Guinea-Bissau1, 12, 52. Furthermore, 
the frequency of the pfdhfr/pfdhps quadruple mutant was 52.8%, which indicates a noteworthy increase since it 
was last documented in 2004 at 15%53. Selection of the pfdhfr/pfdhps quadruple mutant may be explained by the 
recommendation and use of SP for IPTp in Guinea-Bissau, as well as through possible import from neighbouring 
countries with higher levels of the quadruple mutant49, 52, 54, 55.
Conclusion
The methodology presented in this study represents an affordable, high throughput and reliable platform for 
efficient surveillance of spread and emergence of antimalarial drug resistance. With Illumina technology already 
installed in several research facilities in countries with malaria, implementing surveillance of antimalarial drug 
resistance based on this method would be feasible in these locations. In the current study, the analysis of all 
molecular markers of drug resistance was performed for less than 10 USD per sample, but can be run for as lit-
tle as 4 USD per sample. Between 3 and 16 amplicons from 457 P. falciparum patient samples were successfully 
sequenced on a single Miseq v3 flow cell with an average coverage of 2,043 reads and a minimum z-score of 1.96 
applying to all published base calls.
Methods
Patients and malaria parasite samples. A demographic overview of the patients recruited and the sam-
pling process is depicted in Fig. 1. Patients of all ages attending the Bandim and Belem health care centres in 
Guinea-Bissau between October 2014 and March 2016, symptomatic of and diagnosed with P. falciparum malaria 
using malaria RDTs were after informed consent asked to donate blood for filter paper sampling (n = 318). Blood 
samples were drawn in accordance with the relevant guidelines and regulations. An additional 139 patients 
donated their P. falciparum positive RDTs. All patients donating samples had fever (≥37, 5 °C), or a history 
of fever within the past 24 hours and hence qualified as having clinical malaria and were treated according to 
national malaria treatment guidelines. Filter paper samples were collected as venous blood, which was filtered 
with Plasmodipur filters (Europroxima, Arnhem, Netherlands), and dotted on Whatman filter paper nr. 3. Filter 
paper and RDTs were stored at room temperature for 6–9 months before transport to Denmark. Furthermore, 6 
well-described parasite isolates (3D7, Dd2, K1, 7G8, MRA-1238, and MRA-1239) were used as controls. The data 
acquired for these control strains is listed in Table 5.
Ethical approval. Ethical approval and permission for sampling venous blood from malaria patients in 
Guinea-Bissau was given by the ethical review board in Bissau (ref: 022/CNES/INASA/2014, dated September 
17th 2014). Filter paper samples were acquired after written informed consent from the patient or their guardian. 
Blood samples were drawn in accordance with the relevant guidelines and regulations.
DNA extraction. DNA was extracted according to the chelex method described elsewhere56.
Primer design. The experimental protocol was designed to investigate polymorphisms occurring in pfcrt 
(c72–76), pfmdr1 (c86, c1034, c1042 and c1246), pfdhfr (c16, c51, c59, c108 and c164), pfdhps (c431, c436, c437, 
c540, c581 and c613), all of pfK13, and mitochondrial-genome base positions (772, 853, 973, 1283 and 2383). 
All gene-accession numbers, PCR fragments and SNPs are illustrated in Fig. 3. The entire protocol for PCRs and 
Miseq sequencing is illustrated in Figure S1. Primers were designed based on the principles described in Illumina’s 
own Miseq protocol for 16 S metagenomic sequencing library preparation57 and are listed in Supplementary 
Tables S1 (gene specific primers) and S2 (index primers). The concept of gene-specific and index PCR as well 
as characteristics of the primers needed for each step are illustrated in Fig. 2. The gene-specific primers were 
designed to anneal to the P. falciparum gene of interest (at a melting temperature around 60 °C), amplifying a frag-
ment of approximately 500–550 bp, in order to allow for overlap of the two reads conducted during paired-end 
sequencing (350 bp reads). The gene-specific primers all contain a non-annealing overhang on both forward and 
reverse primers. The overhangs are incorporated into both ends of the PCR product during the gene-specific 
PCR, and can now act as annealing site for the indexing primers (Table S2) during the indexing PCR. The over-
hang sequence is based on Illumina’s protocol, because it also serves as primer annealing site for Illumina’s own 
sequencing primers during sequencing. The length and melting temperature are therefore ideal for the tempera-
tures applied by the Miseq during the different sequencing steps. Indexing primers were designed to anneal to the 
overhangs, while themselves containing overhangs consisting of individual 8-base indices and adapter sequences 
that will allow the final PCR product to bind to the sequencing flow cell. Indices were generated using the Barcode 
Generator V. 2.858, indicating a desired barcode length of 8 bases, a distance between barcodes of 4 bases and a 
GC content of at least 40%. All indices used for generation of the presented data are listed in Table S3. All primers 
were ordered at Eurofins Genomics (MWG-Biotech AG, Edersberg, Germany).
PCR reactions and programs. All PCRs were performed with AH PCR Mastermix (AH diagnostics, 
Århus, Denmark). Four different multiplex PCR reactions were run, while Pfcrt.2 and Mito.2 were run as sim-
plex. The multiplex primer combinations are listed in Table S1. Gene-specific primers were used at a 0,065 μM 
final concentration each, together with 1 μl of template DNA in a total reaction volume of 10 μl. The gene-specific 
PCR program consisted of the following steps: Heat activation at 95 °C for 15 minutes, 30 cycles of denaturation 
at 95 °C for 20 seconds, annealing at 57 °C for 2 minutes, and elongation at 72 °C for 2 minutes, and one final elon-
gation at 72 °C for 10 minutes. In order to target relatively uniform coverage of the various amplicons, a subset of 
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the PCR products from the index-specific multiplex PCRs were analysed by qPCR for the relative presence of the 
different fragments (qPCR described below). Based on this data (not presented) the PCR products were mixed 
at a ratio of (multiplex PCRs 1–4) M1:M2:M3:M4/1:0,5:4:6. M5 and amplicon Mito.2 were mixed at a ratio of 
2:1, and Pfcrt.2 was run as simplex on the index PCR. These mixtures of multiplexes were used as template in the 
indexing PCRs. Indexing PCR reactions were performed with a final primer concentration of 0,065 μM together 
with 0,75 μl of gene-specific PCR product (mix of multiplexes or simplex reactions) in a final volume of 11,75 μl. 
The indexing PCR program consisted of the following steps: Heat activation at 95 °C for 15 minutes, 20 cycles of 
denaturation at 95 °C for 20 seconds, annealing at 60 °C for 1 minute, and elongation at 72 °C for 1 minute, and one 
final elongation at 72 °C for 10 minutes. Reactions were performed on either a VWR DuoCycler, VWR UNO96 
(VWR, Søborg, Denmark) or an MWG BIOTECH Primus96 Plus (MWG-BIOTECH, Edersberg, Germany).
qPCR. Primers applied for qPCR analysis are listed in Table S3. qPCR reactions were performed with 
QuantiTect SYBR Green Master Mix (Qiagen, Hilden, Germany), a final primer concentration of 2 μM in a final 
volume of 20 μl. Template for the reaction consisted of 1 μl of PCR product obtained from the Index PCR, diluted 
1:200. The qPCR program consisted of the following steps: Heat activation at 95 °C for 15 minutes, 20 cycles of 
denaturation at 95 °C for 30 seconds, annealing at 54 °C for 40 seconds, and elongation at 68 °C for 50 seconds, and 
one final elongation at 68 °C for 10 minutes. See Figure S2 for example data.
Amplicon purification, dilution and pooling. Pools were made for a maximum of 96 samples, consisting 
of 4 ul of each indexing PCR reaction, totalling 14 pools (corresponding to the 14 individual 96-well plates that 
the PCRs were run in). The amplicons were bead purified with AMPure XP beads (Beckman Coulter, California, 
United States) according to manufacturer’s protocol, using 200 ul PCR product (per pool), and 0.6 x PCR-pool 
volume of beads (=120 ul), in order to eliminate primer dimers of approximately 250 bp. Purified PCR pools 
were analysed on Agilent 2100 Bioanalyser using the Bioanalyser 1000 Kit (Agilent Technologies, Santa Clara, 
CA, USA), to verify the proper elimination of primer dimers, and amplicon sizes of approximately 650–700 bp. 
Concentration of purified PCR pools were measured on a Nanodrop2000 UV-VIS Spectrophotometer (Thermo 
Fisher Scientific, Waltham, MA, USA) and subsequently diluted to 4 nM pools, according to the following equa-
tion: (concentration of pool/(660 * fragment length (bp))) * 1,000,000. Finally, diluted amplicon pools were 
pooled further according to the space each pool was to be given on the flow cell during sequencing (described in 
Figure S3). This was decided based on the amount of samples represented by each pool, multiplied by the amount 
of fragments amplified for each sample in the pool.
Miseq sequencing. The pooled libraries were denatured with NaOH to a final concentration of 1 mM, diluted 
with hybridization buffer and further heat denatured at 96 °C for 2 min before running the sequencing. 5% PhiX 
was included for low diversity libraries. The sequencing was performed with an Illumina MiSeq instrument using 
paired end 2 × 300-bp reads and a MiSeq v3 flow cell according to the manufacturers recommendation. Sequencing 
was carried out by the DTU in-house facility (DTU Multi-Assay Core (DMAC), Technical University of Denmark).
Quality trimming of paired-end sequences and base calling. Raw sequences were quality trimmed 
with Cutadapt59 at a phred score of 20, and primer sequences were trimmed from the 5′-end of the sequences, in 
order to avoid primer bias in the sequenced fragments. Base calling was performed with Assimpler60, a Python 
program developed to compare reads with a custom database, consisting of the 3D7 reference sequences of all 
the analysed genes. Assimpler will then output two files, a column file with the reference base and the called base 
from the sample at all positions in the custom database, as well as a contigs file. Bases were called with a minimum 
z-score of 1.96 corresponding to a p-value below 0,05. The Z-score was calculated as Z = (X − Y)/sqrt(X + Y), the 
number of reads X having the most common nucleotide at that position, and the number of reads Y supporting 
other nucleotides60. Mixed infections were categorised as samples with <75% unanimous reads for a given base 
position for the purpose of generating haplotype data.
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